Cancer Medicine 2018; 7(4):1211--1220

Introduction {#cam41430-sec-0001}
============

In the United States, lung cancer occurs in approximately 225,000 patients and is associated with over 160,000 deaths annually [1](#cam41430-bib-0001){ref-type="ref"}. However, despite the prevalence of this malignancy, the influence and/or interrelation between economic and insurance factors as well as ethnicity have been poorly studied. One recent study did investigate racial/ethnic differences in lung cancer incidence and mortality in women, but found no differences in fully adjusted models [2](#cam41430-bib-0002){ref-type="ref"}. Additionally, another report demonstrated lung cancer rates have dropped faster in Black women than the rates in Whites since the 1990s [3](#cam41430-bib-0003){ref-type="ref"}. Using the Christiana Care Tumor Registry (CCTR) in Delaware, disparities in survival were related to lower socioeconomic status and having Medicaid insurance, but there were no such differences related to race or sex [4](#cam41430-bib-0004){ref-type="ref"}. A National Cancer Database project [5](#cam41430-bib-0005){ref-type="ref"} found income and race (White, Black, and Asian) were not related to survival, but patients with Medicaid or who were uninsured had worse outcomes [5](#cam41430-bib-0005){ref-type="ref"}.

The purpose of our analysis was to study whether marital status, household income, insurance type, and ethnicity play a role in the presentation and prognosis of all patients with NSCLC and those presenting with metastatic disease in the United States. We feel this investigation is unique because we investigate the racial groups in terms of their presenting economic, histopathologic, and marital status and assess whether racial differences account for differing prognoses.

Materials and Methods {#cam41430-sec-0002}
=====================

Data source/cohort selection {#cam41430-sec-0003}
----------------------------

The "SEER‐18" database was available since the year 2000 [6](#cam41430-bib-0006){ref-type="ref"} and covers approximately 28% of the American population [6](#cam41430-bib-0006){ref-type="ref"}. The years 2007--2012 were queried to identify patients with microscopically confirmed NSCLC as their first primary tumor.

Outcome and presenting characteristics were examined for all patients (153,027) and patients with metastatic disease (70,968) for whom sufficient information was collected to assess the outcomes in relation to patient, economic, histopathologic, and insurance variables.

Outcome variables and other covariates {#cam41430-sec-0004}
--------------------------------------

The main purpose of our analysis was to examine whether there were differences in presenting characteristics and outcome in nine different ethnic groups by examining marital status, household income, and insurance type in addition to established histopathologic (tumor location, size, differentiation, stage, and histology), treatment factors (radiation and definitive surgical procedure), and patients factors (age, gender, marital status, presenting year, and SEER registry site). The patients with lung cancer were split into nine different ethnic groups as follows: White non‐Hispanic (White), Black, White Hispanic (Hispanic), American Indian/Alaskan native (AI/AN), Chinese, Japanese, South Asian (Asian Indian and Pakistani), other Asians (OA, Filipino, Thai, Vietnamese, Korean, Kampuchean, Laotian, and Hmong), and other races (OR, Chamorran, Fiji Islander, Guamanian, Hawaiian, Melanesian, Micronesian, New Guinean, Pacific Islander, Polynesian, Samoan, Tahitian, Tongan, unknown, and others) in both the TP and Stage IV populations. The number of Black Hispanic patients was scant in both the TP (1.0%) and the Stage IV groups (0.7%), thus precluding the possibility of considering a separate patient category, and thus, Black Hispanic patients are included in the Black category, similar to a past study [7](#cam41430-bib-0007){ref-type="ref"}. Throughout this manuscript, the term population(s) will refer to total population of patients with lung cancer and those with Stage IV disease, while group(s) will refer to the nine different ethnicities.

At the time of our analysis, SEER did not contain information regarding whether systemic therapy was given, nor does SEER contain information regarding the systemic agents that were used. SEER does contain information including the following: year of diagnosis (1975--2014), sex, patient age (1--84 and 85+), SEER registry location, median household income, insurance, marital status, origin recode (Hispanic, non‐Hispanic), race/ethnicity, tumor location, primary site, sequence number, grade, laterality, tumor size, tumor extension, number of nodes examined, number of nodes positive, TNM stages, Mets at diagnosis, type of surgery, cause of death, vital status, and survival months.

Statistical analysis {#cam41430-sec-0005}
--------------------

Chi‐square and *t*‐tests compared differences between the ethnic groups with respect to treatment and patient/tumor characteristics. Cox proportional hazards models (Therneau, Grambsch) [8](#cam41430-bib-0008){ref-type="ref"} were used to calculate adjusted hazard ratios with their 95% confidence intervals and to show how treatment and other covariates were related to overall survival OS and LCSS. Medicare eligibility was controlled through use of two strata for age at diagnosis (≥65 years old vs. \<65 years) because individual cases will change when they enroll in Medicare.

Results {#cam41430-sec-0006}
=======

Median follow‐up time was calculated by the methods of Schemper and Smith in which death becomes a censored follow‐up time and was noted to be 35 and 31 months in the TP and Stage IV groups, respectively [9](#cam41430-bib-0009){ref-type="ref"}.

Complete demographic and histologic details of the TP (153,027) and Stage IV (70,968) populations can be seen in Table [1](#cam41430-tbl-0001){ref-type="table-wrap"}. Median age in the TP and Stage IV are 68.0 and 67.0, respectively. There was a male predominance to both populations (54.1%‐ TP, and 55.8%‐ Stage IV). The three largest ethnic groups in the TP and Stage IV population were White, Black, and Hispanic and were 74.4%, 12.3%, and 5.7%; and 72.3%, 13.2%, and 6.3%, respectively. A similar proportion of the Stage IV (31.7%) and TP (32.3%) patients presented with a low median family income (\<\$50,000). The majority were married with 51.6% and 51.2% in the TP and Stage IV, respectively. 82.3% and 80.1% of TP and Stage IV patients were insured. Adenocarcinoma was the predominant histology in both populations (52.6%, TP; and 55.5%, Stage IV).

###### 

Demographic characteristics of both the TP and Stage IV patients

                                   All Patients (TP) *N* = 153,027   Stage IV patient *N* = 70,968
  -------------------------------- --------------------------------- -------------------------------
  Age---year, median               68.0                              67.0
  Sex                                                                
  Female                           70,212 (45.9%)                    31,353 (44.2%)
  Male                             82,815 (54.1%)                    39,615 (55.8%)
  Race                                                               
  White Hispanic                   8579 (5.6%)                       4441 (6.3%)
  White non‐Hispanic               114,013 (74.5%)                   51,296 (72.3%)
  Black                            18,852 (12.3%)                    9360 (13.2%)
  Chinese                          2413 (1.6%)                       1261 (1.8%)
  Japanese                         1229 (0.80%)                      567 (0.80%)
  South Asian                      451 (0.29%)                       238 (0.34%)
  Other Asians                     4831 (3.2%)                       2544 (3.6%)
  Other Races                      1957 (1.3%)                       943 (1.3%)
  American Indian/Alaskan Native   702 (0.46%)                       318 (0.45%)
  SEER registry                                                      
  Alaska Natives                   199 (0.13%)                       76 (0.11%)
  Atlanta                          4629 (3.0%)                       2226 (3.1%)
  California excl SF/SJM/LA        30,007 (19.6%)                    14,304 (20.2%)
  Connecticut                      8088 (5.30%)                      3639 (5.1%)
  Detroit                          9852 (6.4%)                       4632 (6.5%)
  Greater Georgia                  14,260 (9.3%)                     6380 (9.0%)
  Hawaii                           2375 (1.6%)                       1159 (1.6%)
  Iowa                             6805 (4.4%)                       3205 (4.5%)
  Kentucky                         13,916 (9.1%)                     5980 (8.4%)
  Los Angeles                      11,437 (7.5%)                     5789 (8.2%)
  Louisiana                        10,783 (7.0%)                     4767 (6.7%)
  New Jersey                       17,451 (11.4%)                    7796 (11.0%)
  New Mexico                       2610 (1.7%)                       1215 (1.7%)
  Rural Georgia                    353 (0.23%)                       140 (0.20%)
  San Francisco--Oakland           7081 (4.6%)                       3469 (4.9%)
  San Jose--Monterey               3203 (2.1%)                       1635 (2.3%)
  Seattle                          8271 (5.4%)                       3726 (5.3%)
  Utah                             1707 (1.1%)                       830 (1.2%)
  Income                                                             
  \<\$50,000                       49,407 (32.3%)                    22,524 (31.7%)
  \$50,000--74,000                 81,027 (52.9%)                    37,933 (53.5%)
  ≥75,000                          22,593 (14.8%)                    10,511 (14.8%)
  Marital status                                                     
  Divorced                         18,851 (12.3%)                    8815 (12.4%)
  Married                          78,957 (51.6%)                    36,349 (51.2%)
  Separated                        1785 (1.2%)                       895 (1.3%)
  Single                           21,126 (13.8%)                    10,872 (15.3%)
  Unknown                          6032 (3.9%)                       2866 (4.0%)
  Domestic Partner                 126 (0.082%)                      60 (0.084%)
  Widowed                          26,150 (17.1%)                    11,111 (15.7%)
  Tumor stage                                                        
  Unknown                          3174 (2.0%)                       0
  I                                34,255 (22.3%)                    0
  II                               7825 (5.1%)                       0
  III                              39,979 (26.1%)                    0
  IV                               70,968 (46.3%)                    70,968 (100.0%)
  Insurance                                                          
  Insured                          125,876 (82.3%)                   56,859 (80.1%)
  Medicaid                         20,741 (13.6%)                    10,324 (14.5%)
  Uninsured                        5272 (3.4%)                       3145 (4.4%)
  Unknown                          1138 (0.74%)                      640 (0.96%)
  Lateral location                                                   
  Bronchus, Left                   2427 (1.6%)                       1311 (1.8%)
  Bronchus, Right                  2427 (2.2%)                       1875 (2.6%)
  Bronchus, Unknown                168 (0.11%)                       103 (0.15%)
  Left Lower                       17,384 (11.4%)                    7266 (10.2%)
  Left Upper                       35,216 (23.0%)                    14,827 (20.9%)
  Left NOS                         4733 (3.1%)                       2993 (4.2%)
  Lung, NOS                        6207 (4.1%)                       5382 (7.6%)
  Left Overlapping                 507 (0.32%)                       249 (0.35%)
  Right Lower                      22,457 (14.7%)                    9476 (13.4%)
  Right Middle                     6376 (4.2%)                       2848 (4.0%)
  Right Upper                      45,478 (29.7%)                    19,134 (27.0%)
  Right NOS                        7460 (4.9%)                       4921 (6.9%)
  Right Overlapping                1268 (0.83%)                      583 (0.82%)
  Histology---No. (%)                                                
  Adenocarcinoma                   80,499 (52.6%)                    39,415 (55.5%)
  Squamous Cell Ca                 41,573 (27.2%)                    14,239 (20.0%)
  Non‐small‐cell Ca, NOS           22,886 (15.0%)                    13,603 (19.2%)
  Large Cell Ca                    4519 (3.0%)                       2301 (3.2%)
  Adenosquamous Cell Ca            2442 (1.6%)                       921 (1.3%)
  Others                           1108 (0.72%)                      489 (0.69%)
  Grade                                                              
  Well, I                          8365 (5.4%)                       1795 (2.5%)
  Moderately, II                   30,010 (19.6%)                    7974 (11.2%)
  Poorly, III                      45,364 (29.6%)                    19,445 (27.3%)
  Undifferentiated, IV             2497 (1.6%)                       1142 (1.6%)
  Unknown                          66,791 (43.8%)                    40,612 (57.2%)
  Definitive surgical procedure    39,105 (25.6%)                    
  Radiation given                  64,552 (41.8%)                    33,689 (47.5%)
  Year of diagnosis                                                  
  2007                             25,396 (16.6%)                    11,589 (16.3%)
  2008                             25,529 (16.7%)                    11,572 (16.3%)
  2009                             25,650 (16.8%)                    11,848 (16.7%)
  2010                             25,631 (16.7%)                    12,135 (17.1%)
  2011                             25,459 (16.6%)                    11,807 (16.6%)
  2012                             25,362 (16.6%)                    12,017 (16.9%)
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Table [S1](#cam41430-sup-0001){ref-type="supplementary-material"} supplemental contains the unadjusted demographic, histologic, and treatment details in the TP and used Whites as the reference group. Blacks were presented with younger age, more males, lower median household income, more uninsured, higher stages, lower percentage of squamous cell carcinomas, lower rates of definitive surgery, and lower OS/LCSS. Hispanics were presented at a younger age, higher median household income, more uninsured, higher percentage of metastatic disease, higher percentage of adenocarcinomas, and lower rates of definitive surgery, but had a similar OS/LCSS. The Japanese were presented with a highest mean age (72.8), the only female predominance (51.2%), and the highest rates of insurance (96.4%), but there were a similar OS and LCSS compared to Whites. Whites were presented with the higher percentage of Stage I disease (23.4%) than all except for the South Asian and AI/AN. South Asians were presented with the highest percentage of metastatic disease at 52.8%. The Chinese were presented with the highest percentage of adenocarcinomas (69.4%), while AI/AN were presented with the highest percentage of squamous cell carcinomas (30.8%). Whites had significantly higher rates of definitive surgical procedures except for the Chinese, Japanese, and South Asians. As compared to the White population, OS and LCSS were significantly greater in the Chinese, South Asians, other Asians, and other racial groups. Blacks had a lower OS and LCSS. Unadjusted OS by ethnic group can be found in Figure [1](#cam41430-fig-0001){ref-type="fig"}A.

![(A) Unadjusted overall survival by ethnic group in the total population. (B) Multivariable‐adjusted overall survival by ethnic group in the total population.](CAM4-7-1211-g001){#cam41430-fig-0001}

Multivariable analyses for OS and MVA‐adjusted OS in the TP can be seen in Table [2](#cam41430-tbl-0002){ref-type="table-wrap"} and Figure [1](#cam41430-fig-0001){ref-type="fig"}B. Advancing age (*P* \< 0.0001, HR = 1.185) and male sex (*P* \< 0.0001, HR = 1.245) were associated with worse OS. Whites had a lower OS than all races (HR = 0.705--0.977) except for AI/AN who had a similar OS (*P* = 0.4890, HR = 0.963). OS was lower for lower (*P* = 0.0097, HR = 1.024) and better for higher median household incomes (*P* \< 0.001, HR = 0.936). Insured patients had a better OS than the uninsured, those on Medicaid and those with unknown insurance (all *P* \< 0.0001, HR = 1.197--1.246). Married patients had a better OS than separated, single, widowed, and unknown (all *P* ≤ 0.0004, HR = 1.062--1.166). As compared to Stage I, Stages II‐IV had a worse OS with increasing HRs with stage (all *P* \< 0.0001, HR = 1.622--3.290). The lower lobes and mainstem bronchi locations were associated with worse OS. All histologies had a worse OS (all *P* \< 0.0001, HR = 1.113--1.536) than adenocarcinomas. Compared to well‐differentiated tumors, other tumor grades had worse OS (all *P* \< 0.0001, HR = 1.372--1.731). Patients who received radiation (*P* \< 0.0001, HR = 0.759) or definitive surgery (*P* \< 0.0001, HR = 0.331) had a better OS. OS by insurance, income, and marital status for TP can be seen in Figure [2](#cam41430-fig-0002){ref-type="fig"}A--C.

###### 

Multivariate analysis for OS in TP, *N* = 153,207

  All (*N* = 153,207)              *P*‐value   Hazard ratio
  -------------------------------- ----------- --------------
  Age---year                       1.185       \<0.0001
  Sex                                          
  Female                           --          1.0
  Male                             \<0.0001    1.245
  Race                                         
  White non‐Hispanic               --          1.0
  White Hispanic                   \<0.0001    0.937
  Black                            0.0205      0.977
  Chinese                          \<0.0001    0.705
  Japanese                         0.0061      0.903
  South Asian                      \<0.0001    0.733
  Other Asians                     \<0.0001    0.762
  Other Races                      \<0.0001    0.792
  American Indian/Alaskan Native   0.4890      0.963
  SEER Registry                                
  Alaska Natives                   0.3002      1.111
  Atlanta                          0.1724      1.032
  California excl SF/SJM/LA        0.0003      1.060
  Connecticut                      --          1.0
  Detroit                          0.3908      1.017
  Greater Georgia                  \<0.0001    1.095
  Hawaii                           \<0.0001    1.149
  Iowa                             0.0002      1.081
  Kentucky                         \<0.0001    1.135
  Los Angeles                      0.3514      0.983
  Louisiana                        \<0.0001    1.141
  New Jersey                       0.0117      1.044
  New Mexico                       0.6428      1.014
  Rural Georgia                    0.9719      0.998
  San Francisco--Oakland           0.0325      1.046
  San Jose--Monterey               0.1455      1.040
  Seattle                          0.2381      1.024
  Utah                             0.0011      1.114
  Income                                       
  \<\$50,000                       0.0097      1.024
  \$50,000--74,000                 --          1.0
  ≥75,000                          \<0.0001    0.936
  Insurance                                    
  Insured                                      1.0
  Medicaid                         \<0.0001    1.200
  Uninsured                        \<0.0001    1.246
  Unknown                          \<0.0001    1.197
  Marital status                               
  Married                          --          1.0
  Divorced                         \<0.0001    1.144
  Separated                        0.0001      1.120
  Single                           \<0.0001    1.166
  Unknown                          0.0004      1.062
  Domestic Partner                 0.3785      1.124
  Widowed                          \<0.0001    1.147
  Tumor stage                                  
  I                                --          1.0
  II                               \<0.0001    1.622
  III                              \<0.0001    1.994
  IV                               \<0.0001    3.290
  Lateral location                             
  Right upper                      --          1.0
  Bronchus, Left                   \<0.0001    1.232
  Bronchus, Right                  \<0.0001    1.297
  Bronchus, Unknown                0.0169      1.226
  Left Lower                       \<0.0001    1.062
  Left Upper                       0.0874      1.015
  Left NOS                         \<0.0001    1.228
  Lung, NOS                        \<0.0001    1.211
  Left Overlapping                 0.0077      1.152
  Right Lower                      \<0.0001    1.083
  Right Middle                     0.2052      1.022
  Right NOS                        \<0.0001    1.253
  Right Overlapping                \<0.0001    1.313
  Histology---No. (%)                          
  Adenocarcinoma                   --          1.0
  Adenosquamous                    \<0.0001    1.196
  Large Cell                       \<0.0001    1.176
  Nonsmall Cell                    \<0.0001    1.149
  Others                           \<0.0001    1.536
  Squamous                         \<0.0001    1.113
  Grade                                        
  Well, I                          --          1.0
  Moderately, II                   \<0.0001    1.372
  Poorly, III                      \<0.0001    1.629
  Undifferentiated, IV             \<0.0001    1.731
  Unknown                          \<0.0001    1.537
  Definitive Surgical Procedure    \<0.0001    0.331
  Radiation                        \<0.0001    0.759
  Year of diagnosis                            
  2007                             --          1.0
  2008                             0.0664      0.982
  2009                             0.0002      0.963
  2010                             \<0.0001    0.956
  2011                             \<0.0001    0.914
  2012                             \<0.0001    0.891
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![Multivariable‐adjusted overall survival in the total population. (A) by insurance; (B) by income; (C) by marital status.](CAM4-7-1211-g002){#cam41430-fig-0002}

Multivariable analyses for OS for the Stage IV population can be seen in Table [3](#cam41430-tbl-0003){ref-type="table-wrap"}. Age (*P* \< 0.0001, HR = 1.017) and male sex (*P* \< 0.0001, HR = 1.233) were associated with worse OS. All races had better OS than Whites (HR = 0.709--0.898) except for AI/AN and Blacks who had a similar OS. OS decreased for lower incomes (*P* = 0.0484, HR = 1.025) and increased for higher incomes (*P* \< 0.001, HR = 0.934). Insured patients had a better OS than uninsured and those with Medicaid and unknown insurance (all *P* \< 0.0001, HR = 1.195--1.277). Married patients or those with a domestic partner had better OS than those not living in a stable partner situation (divorced, *P* \< 0.0001, HR = 1.154; widowed, *P* \< 0.0001, HR = 1.149; separated, *P* = 0.0009, HR = 1.134; and unknown, *P* = 0.0023, HR = 1.069). Involvement of mainstem bronchi and right lower lobe was deleterious for OS. All other histologies were associated with a worse OS compared to adenosquamous cell carcinoma or adenocarcinoma (all *P* \< 0.0001, HR = 1.107--1.482). All tumors differentiation compared to well‐differentiated had significantly worse OS (all *P* \< 0.0001, HRs 1.258--1.702). Palliative radiation significantly improved OS (*P* \< 0.0001, HRs 0.896). Starting in the year 2010, OS started to significantly improve with progressively lower HRs each year.

###### 

Multivariate Analysis for OS in Stage IV population, *N* = 70,968

  All (*n* = 70,968)               *P*‐value   Hazard ratio
  -------------------------------- ----------- --------------
  Age---year                       \<0.0001    1.017
  Sex                                          
  Female                           --          1.0
  Male                             \<0.0001    1.233
  Race                                         
  White non‐Hispanic               --          1.0
  White Hispanic                   \<0.0001    0.924
  Black                            0.1704      0.982
  Chinese                          \<0.0001    0.709
  Japanese                         0.0281      0.898
  South Asian                      \<0.0001    0.729
  Other Asians                     \<0.0001    0.776
  Other Races                      \<0.0001    0.800
  American Indian/Alaskan Native   0.9669      0.997
  SEER Registry                                
  Alaska Natives                   0.3708      1.136
  Atlanta                          0.6764      0.987
  California excl SF/SJM/LA        0.2900      1.022
  Connecticut                      --          1.0
  Detroit                          0.7774      1.007
  Greater Georgia                  0.0971      1.042
  Hawaii                           0.0229      1.097
  Iowa                             0.0442      1.057
  Kentucky                         0.0487      1.052
  Los Angeles                      0.0346      0.950
  Louisiana                        0.0044      1.078
  New Jersey                       0.9390      0.998
  New Mexico                       0.9163      1.004
  Rural Georgia                    0.9052      1.011
  San Francisco--Oakland           0.5813      1.015
  San Jose--Monterey               0.4499      0.975
  Seattle                          0.9550      1.001
  Utah                             0.6367      1.020
  Income                                       
  \<\$50,000                       0.0484      1.025
  \$50,000--74,000                 --          1.0
  ≥75,000                          \<0.0001    0.934
  Insurance                                    
  Insured                          --          1.0
  Medicaid                         \<0.0001    1.195
  Uninsured                        \<0.0001    1.273
  Unknown                          \<0.0001    1.277
  Marital status                               
  Married                          --          1.0
  Divorced                         \<0.0001    1.154
  Separated                        0.0009      1.134
  Single                           \<0.0001    1.167
  Unknown                          0.0023      1.069
  Domestic Partner                 0.1157      1.283
  Widowed                          \<0.0001    1.149
  Lateral location                             
  Right upper                      --          1.0
  Bronchus, Left                   \<0.0001    1.210
  Bronchus, Right                  \<0.0001    1.330
  Bronchus, Unknown                0.0104      1.308
  Left Lower                       0.0607      1.029
  Left Upper                       0.5952      1.006
  Left NOS                         \<0.0001    1.181
  Lung, NOS                        \<0.0001    1.214
  Left Overlapping                 0.0241      1.168
  Right Lower                      0.0037      1.041
  Right Middle                     0.4196      0.982
  Right NOS                        \<0.0001    1.163
  Right Overlapping                0.0002      1.186
  Histology---No. (%)                          
  Adenocarcinoma                   --          1.0
  Adenosquamous                    0.0831      1.067
  Large Cell                       \<0.0001    1.174
  Nonsmall Cell                    \<0.0001    1.186
  Others                           \<0.0001    1.482
  Squamous                         \<0.0001    1.107
  Grade                                        
  Well, I                                      
  Moderately, II                   \<0.0001    1.258
  Poorly, III                      \<0.0001    1.627
  Undifferentiated, IV             \<0.0001    1.702
  Unknown                          \<0.0001    1.645
  Radiation                        \<0.0001    0.896
  Number of Nodes examined                     
  Year of Diagnosis                            
  2007                             --          1.0
  2008                             0.4704      0.990
  2009                             0.0684      0.976
  2010                             0.0332      0.971
  2011                             \<0.0001    0.937
  2012                             \<0.0001    0.899
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Discussion {#cam41430-sec-0007}
==========

A major finding of our analysis is Blacks often present at a younger age, have worse prognostic characteristics, and a lower OS/LCSS than Whites. However, after multivariable adjustment, Blacks have a better OS in the TP and similar OS in the Stage IV patients as compared to Whites. Blacks present with many poor prognostic factors including the following: lower median household income, single/widowed partnership status, higher male predominance, more uninsured, higher stages, and lower rates of definitive surgery. However, Blacks did present at a younger age and have a lower percentage of squamous cell carcinomas, both of which are associated with a better prognosis. As insurance, presentation stage, and surgical eligibility can be altered, there is hope that outcomes for Blacks can be improved with better access to insurance and by increased CT screening [10](#cam41430-bib-0010){ref-type="ref"}. In comparison with Whites, Hispanics presented with a higher proportion of several risk factors associated with poor prognosis including more uninsured, a lower proportion of Stage I/II tumors, and lower rates of definitive surgery, but there was no detrimental effect on the unadjusted OS or LCSS in the TP. Furthermore, MVAs demonstrated OS was significantly better for Hispanics compared to Whites in both the TP and Stage IV populations. It should be noted that previous analysis demonstrated this preferential OS benefit associated with Hispanics may be limited to those who are foreign‐born as compared to those born in the United States [11](#cam41430-bib-0011){ref-type="ref"}. Because the East Asian populations are enriched for the EGFR mutation tumors [12](#cam41430-bib-0012){ref-type="ref"}, it is not surprising the Chinese, South Asian, other Asians, and Japanese had a better adjusted OS in the TP/Stage IV populations, although this analysis lacks details on the mutational status of tumors.

In both MVAs for OS in the TP and Stage IV populations, male sex, poorer tumor differentiation, higher tumor stage, and advanced age were shown to be poor prognostic features and have been well established [13](#cam41430-bib-0013){ref-type="ref"}, [14](#cam41430-bib-0014){ref-type="ref"}. Furthermore, palliative radiation therapy was found to be important for OS in the Stage IV population. Involvement of the mainstem bronchi and lower lobes was associated with worse OS. Although it can be hypothesized the involvement of the mainstem bronchi can contribute to an increased mortality due to postobstructive pneumonia and/or hypoxia, the survival decrement noted with the lower lobe locations may be due to a greater involvement of normal lung volumes. Because of the known ability of radiation to alleviate symptoms in Stage IV lung cancer [15](#cam41430-bib-0015){ref-type="ref"}, we feel the OS benefit noted with radiation in this study may be due to its palliation of central‐based obstructive masses.

Since 2010 (2009 in TP), a consistent improvement in OS was noted in both populations. Although our analysis is unable to identify reasons for this progressive improvement, we feel the reasons are multifactorial. We speculate better staging with frequent use of CT/PET scanning [16](#cam41430-bib-0016){ref-type="ref"} is associated with better outcomes. However, the benefits in the Stage IV population may have also been due to the recognition of chemotherapeutic regimens based upon histology [17](#cam41430-bib-0017){ref-type="ref"} and benefits of targeted therapeutic agents for EGFR mutations [18](#cam41430-bib-0018){ref-type="ref"} and EML4‐ALK translocations [19](#cam41430-bib-0019){ref-type="ref"}. Unfortunately, SEER does not contain information regarding the mutations or systemic therapy.

In both patient populations, MVA demonstrated higher income was positively associated with OS. Lower socioeconomic status was previously shown to affect cancer mortality and to be associated with modifiable risk factors such as smoking, diet, BMI, and lower levels of physical activity [20](#cam41430-bib-0020){ref-type="ref"}. Unfortunately, these modifiable risk factors are not contained within SEER‐18, but information concerning insurance is available and is more strongly correlated with OS than income. Furthermore, cigarette smoking is noted to be more prevalent in lower socioeconomic groups [21](#cam41430-bib-0021){ref-type="ref"} and could account for the lower OS associated with economic factors. The effects of not being insured have greater effect on OS not only in this population group, but in our companion article concerning surgical patients in these same ethnic groups. It is interesting to note patients with Medicaid have similar hazard ratios for adverse outcomes as compared to those without insurance. We hypothesize the poor outcomes noted in the Medicaid population may be due to the socioeconomic conditions of individuals who have this coverage or possibly due to provider differences. Similar poor outcomes of patients who are receiving Medicaid or who are uninsured have recently been reported in patients with testicular cancers, glioblastomas, and head and neck cancers [22](#cam41430-bib-0022){ref-type="ref"}, [23](#cam41430-bib-0023){ref-type="ref"}, [24](#cam41430-bib-0024){ref-type="ref"}. Nevertheless, hopefully, Medicaid expansion will provide better health outcomes for patients with cancer and has already been associated with increases in medication adherence, preventive care, and healthcare quality [25](#cam41430-bib-0025){ref-type="ref"}. In a database of 75 countries obtained from the World Bank and WHO (1990--2010), unemployment was associated with increased lung cancer mortality, but only in men [26](#cam41430-bib-0026){ref-type="ref"}. The effects of unemployment on cancer mortality appeared to be mitigated by universal health coverage. Our results suggest the type of insurance can affect the prognosis of patients with short expected survivals, that is, Stage IV. Although higher lung cancer mortality was recently noted in the mid‐South [27](#cam41430-bib-0027){ref-type="ref"} and our analysis indicates there is worse OS in Kentucky and Louisiana in both patient populations, the effects of geography on poor prognosis in our study were not limited to those areas. Our results show married patients or those with a domestic partner have a significantly longer survival, even in metastatic disease. Although our results conflict with those of a past investigation [28](#cam41430-bib-0028){ref-type="ref"} in patients with lung cancer, other investigators have noted unmarried patients with lung cancer had a greater incidence of depression, less social support, and a survival decrement [29](#cam41430-bib-0029){ref-type="ref"}.

SEER‐18 lacks many variables including smoking, diet, BMI, levels of physical activity, type of chemotherapeutic agents, radiation doses/volumes, surgical complications, medical office visits, and patient comorbidities. Therefore, our analysis cannot account for these variables**.**

It should be noted that there are past studies that have shown that Blacks have uniformly worse outcomes than Whites [30](#cam41430-bib-0030){ref-type="ref"}, [31](#cam41430-bib-0031){ref-type="ref"}, [32](#cam41430-bib-0032){ref-type="ref"}, [33](#cam41430-bib-0033){ref-type="ref"}, our study is more comprehensive in that we assess nine different ethnic groups and because we adjust for marital, economic, histopathologic, and insurance variables. Our comprehensive analysis allows for a unique finding that Blacks may have better (TP) or similar (Stage IV) outcomes as compared to the White population. Therefore, because the White Hispanic and Black populations present at more advanced stages and have better outcomes, we feel that increased lung cancer screening would be preferentially better in these patients. Such a clear pathway for survival improvement in the White population cannot be ascertained in our population. Unfortunately, SEER does not contain genomic information by race or otherwise. However, at present, genomic information in patients with lung cancer is not prevalent enough (5% or 10% frequency) in ethnic groups other than Whites in the Cancer Genome Atlas (TCGA) [34](#cam41430-bib-0034){ref-type="ref"}.

Conclusion {#cam41430-sec-0008}
==========

In summary, our analysis does demonstrate racial disparities do exist in the presentation of the Black and Hispanic populations with lung cancer. Both groups were presented with lower rates of insurance, higher stages, and lower rates of definitive surgery. Blacks had a lower OS/LCSS, but when adjusted for histopathologic, therapeutic, marital status, and economic factors, they had a better OS in the TP than Whites. Disparities in income, marital status, and insurance rather than ethnicity affect OS of patients with lung cancer. Because of their more common presentation with advanced disease, the Black and Hispanic groups may benefit preferentially from screening. Our analyses support the expansion of lung cancer screening to people at higher risk of presenting with advanced stage secondary to limited access to health care due to lower income and lack of insurance, particularly in the Black and Hispanic groups. Specifically, affordable and quality healthcare needs to be provided to these at‐risk populations possibly by education/health literacy and care navigators/coordinators. However, the outcome improvement in the White population may need attention in areas other than just screening.
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